MedTrace Logo

Effect of Paricalcitol on Markers of Inflammation in Hemodialysis Patients

NCT00294866 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2010-04-08

No results posted yet for this study

Summary

Studies have shown that patients with ESRD on hemodialysis have high levels of inflammatory markers which may contribute to the high rates of cardiovascular disease and mortality seen in these patients. Vitamin D use in dialysis patients has been shown to have a survival benefit, with paricalcitol at advantage over calcitriol. Since there is some evidence for involvement of the vitamin D receptor in inflammation, this study is designed to look for an effect of paricalcitol on markers of inflammation in hemodialysis patients.

Conditions

Interventions

DRUG

Paricalcitol

Patients randomized to either receive Paricalcitol or have it held. After 4 weeks they are switched to the opposite intervention.

Sponsors & Collaborators

  • Abbott

    collaborator INDUSTRY

  • Fresenius Medical Care North America

    lead INDUSTRY

Principal Investigators

  • Mark R Kaplan, M.D. · Fresenius Medical Care North America

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-03-31
Primary Completion
2008-01-31
Completion
2008-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00294866 on ClinicalTrials.gov